SOUTH SAN FRANCISCO, Calif., May 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events. About IDEAYA Biosciences IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates cap ...

Over 18-years at leading life sciences and strategy consulting companies, including Revolution Medicines, Guardant Health, Onyx Pharmaceuticals, and McKinsey & Company SOUTH SAN FRANCISCO, Calif., May 28, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Daniel A. Simon, will join the company as its Chief Business Officer in August 2024. "We are thrilled to welcome Dani ...

Core Insights - IDEAYA Biosciences announced preliminary clinical results for darovasertib, a first-in-class oral small molecular inhibitor of protein kinase C (PKC), in a Phase 2 trial for uveal melanoma at the 2024 ASCO Annual Meeting [1][5] Group 1: Clinical Trial Details - The Phase 2 trial involved 15 patients with localized uveal melanoma, treated with darovasertib 300mg twice daily [2] - An initial safety cohort of 3 patients was treated for one month, followed by 12 patients in an expansion cohort for up to six months [2] - As of the database lock, 11 patients completed primary treatment, with 4 remaining on neoadjuvant treatment and 6 receiving adjuvant darovasertib [3] Group 2: Efficacy and Safety Results - Approximately 67% (6 of 9 patients) had confirmed eye preservation, converting to plaque brachytherapy or external beam radiotherapy [3][8] - Median tumor shrinkage was approximately 39% after six months of treatment [3][8] - Darovasertib was generally well tolerated, with drug-related adverse events primarily Grade 1 or Grade 2; 13% reported at least one Grade 3 adverse event, with no serious adverse events observed [4][8] Group 3: Upcoming Presentation - Additional clinical data and follow-up will be presented at the ASCO 2024 oral presentation scheduled for June 3, 2024 [5][9] - The presentation will focus on the safety and efficacy of darovasertib for localized ocular melanoma [9]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38915 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 47-4268251 (State or oth ...

Exhibit 99.1 IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update • ASCO 2024 oral presentation of darovasertib neoadjuvant UM Phase 2 investigator-sponsored trial on June 3rd, and targeting neoadjuvant UM update in over 30 patients from Phase 2 company-sponsored trial and regulatory guidance both in H2 2024 South San Francisco, CA, May 7, 2024– IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and developm ...

ASCO 2024 oral presentation of darovasertib neoadjuvant UM Phase 2 investigator-sponsored trial on June 3rd, and targeting neoadjuvant UM update in over 30 patients from Phase 2 company-sponsored trial and regulatory guidance both in H2 2024 Selected move-forward Phase 2 dose for IDE397 in MTAP squamous NSCLC, based on clinical efficacy observed in this indication, including multiple PRs by RECIST 1.1; and multiple PRs by RECIST 1.1 have also been observed in MTAP bladder cancer Enrollment is ongoing in th ...

SOUTH SAN FRANCISCO, Calif., May 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an upcoming investor relations event. RBC Capital Markets Global Healthcare ConferenceTuesday, May 14th, 2024 at 3:05 PM ET Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Gregory Renza, Director and Senior Biotechnology Research Analyst A live audio w ...

SOUTH SAN FRANCISCO, Calif., April 26, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 25, 2024, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 62,800 shares of the Company's common stock to two newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2 ...

Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024, at 9:51 AM CDT The abstract summary will be available on Thursday, May 23, 2024 at ~5:00pm ET SOUTH SAN FRANCISCO, Calif., April 24, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that interim results from the investigator-sponsored Phase 2 trial evaluating darovasertib safety and efficacy as neoadjuvant ...

Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on AE profile and preliminary clinical efficacy observed, including multiple partial responses by RECIST 1.1  Evaluating over 40 MTAP PDX preclinical models, squamous NSCLC was identified as the most sensitive tumor type to IDE397 monotherapy where ~50% of the models observed tumor regressions at 30mg/kg QD  Over 100,000 global annual incidence of MTAP-deletion squamous NSCLC SOUTH SAN FRANCISCO, C ...